Milnacipran
As of the edition of 20 October 2026, Milnacipran is a small molecule: marketed, first approved in 2009 (US); acts on SLC6A2 and SLC6A4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Savella
- First approved
- 14 January 2009 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- AbbVie
- Registered trials
- 36, 8 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system; Immune system; Skin and connective tissue; Heart and blood vessels; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Milnacipran.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 2 | 5 | 2 | 0 | 3 |
| Phase 3 | 13 | 9 | 0 | 4 |
| Phase 4 | 15 | 12 | 0 | 1 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Acquired holder | 2023 to now |
| Cypress Bioscience | Originator | 2009 to 2023 |